ArticleFrontiers in molecular biosciences2025
A prognostic nomogram for predicting overall survival in gastric signet ring cell carcinoma patients: a SEER database and Chinese registry analysis.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lauren classification-based combined model integrating clinicopathological and spectral CT features for disease-free survival prediction in gastric cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Development and validation of nomograms for predicting overall survival and cancer-specific survival in female gastric signet-ring cell carcinoma: a SEER database analysis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Gastric signet ring cell carcinoma (GSRC) is a distinct gastric cancer (GC) subtype. This study aimed to develop and validate a nomogram to predict overall survival (OS) and guide clinical decision-making. Methods: This study included 2,203 GSRC patients from the SEER database (2010-2019), randomly split into a modeling cohort (n = 1,542) and an internal validation cohort (n = 661). An external cohort of 74 patients from the Second Affiliated Hospital of Nanjing Medical University (2019-2024; median follow-up 34 months) was used for validation. Predictor variables-age, sex, chemotherapy, lymph node ratio (LNR), T and M categories, tumor size, and tumor number-were included in a cox proportional hazard model. A nomogram was derived from the cox model and internally validated using 1,000 bootstrap resamples. Discrimination, calibration, and decision curve analysis (DCA) evaluated model performance. Results: The nomogram included age, chemotherapy, LNR, T and M categories, and tumor size. In the modeling cohort, time-dependent area under the receiver operating characteristic curve (AUC) was 0.79, 0.85, and 0.85 at 12, 36, and 60 months; internal validation AUCs were 0.79, 0.85, and 0.85. In the external cohort, AUC at 36 months was 0.91 (primary horizon), with exploratory IPCW-AUCs of 1.00 at 12 and 60 months due to class imbalance. Calibration showed close agreement between predicted and observed OS, and DCA demonstrated clinical net benefit across relevant thresholds. Conclusion: This study developed a nomogram for OS prediction in GSRC patients, supporting risk stratification and clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.